CROs/Service Providers

ICON Reports Banner Year; Central Lab Business Swings Back

Friday, February 16, 2007

In line with the banner year shared by much of clinical trials industry, the Dublin, Ireland-based contract research organization (CRO) ICON reported big gains in 2006. The company generated $129 million in net revenue, a 46% increase compared with $88.1 million during the same period in 2005. The company had full year revenues of $455.6 million in 2006 compared with $342.8 million in 2005, representing an increase of 33%. ICON’s operating income rose 69% to $51.9 million in 2006 compared with $30.8 million in 2005.

[Read More]

Quintiles Invests in Biotech

Friday, January 12, 2007

Quintiles Transnational’s strategic partnering unit, NovaQuest, funded a total of $342 million in 16 investments into emerging biotech companies. Quintiles will also provide marketing expertise, strategic development and possibly product development and commercialization. The unit of NovaQuest charged with funding emerging biotech companies is called eBio.

[Read More]

eClinical Market Has Strong Year

Monday, November 27, 2006

In its third quarter, Morrisville, N.C.-based eClinical service provider etrials reported 40% growth in services revenue to $4.4 million.Net revenues during the same period in 2005 were $3.2 million. The company reported operating income of $178,331 compared with an operating loss of $148,618 in 2005 during the same period. etrials went public in 2005 in a reverse merger.

[Read More]

Charles River Laboratories Acquires U.S. Phase I Unit

Tuesday, October 31, 2006

Wilmington, Mass.-based Charles River Laboratories has stepped up its clinical research presence with the purchase of Northwest Kinetics, a 150-bed unit early phase clinical pharmacology unit in Tacoma, Wash. The deal is worth $29.5 million and may signal that Charles River has interest in expanding its clinical development business, after selling off much of that to Kendle last year. Watch for the in depth story in an upcoming issue of our CWWeekly newsletter.

[Read More]

Phase I Doesn’t Faze Them

Wednesday, October 25, 2006

It was interesting to see Waltham, Mass.-based Parexel, a global contract research organization (CRO), remaining unfazed in the hot phase I clinical research market. Earlier this month, Parexel agreed to acquire California Clinical Trials and Behavioral and Medical Research for $65 million. A key part of the deal is a 51-bed phase I unit that would boost Parexel’s presence in the phase I market.

[Read More]

In India, A Pairing Born Of Necessity

Monday, October 9, 2006

India’s clinical research market entered a new era in January 2005 with the signing of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. TRIPS requires the country to honor all product patents issued after 1995.

[Read More]

INC Research Acquires PRC; Expands Late Stage Capabilities

Wednesday, September 27, 2006

INC Research, a Raleigh, N.C.-based contract research organization (CRO),has acquired Pharmaceutical Research (PRC), a late stage–focused CRO based in Hatboro, Penn. INC was actively searching for an opportunity to grow in the area of late stage trials. The acquisition allows INC to expand its phase IIIb/IV capabilities. About 90% of INC’s business is in the phase I to III market, while 70% of the trials that PRC services are in phase IIIb/IV. “PRC has a strong reputation in that area, and so they were an obvious choice for us to talk to. It was also culturally similar with some great goals for growth,” John Potthoff, president and chief operating officer, INC Research told CWWeekly.

[Read More]

Medical Device CROs Setting Up Shop in Emerging Markets

Wednesday, September 20, 2006

Alquest, a medical device focused contract research organization (CRO) based in Minneapolis, Minn., has launched services in India. The company claims to be the first such CRO to expand medical device offerings into the emerging India trials market. Medical device companies are particularly afflicted by challenging patient recruitment rates, and Alquest feels many companies will head to India to shave costs.

[Read More]